ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and...
The following is issued on behalf of ChromaDex (NASDAQ: CDXC).
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr....
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023....